MesteroloneCAS# 1424-00-6 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1424-00-6 | SDF | Download SDF |
| PubChem ID | 15020 | Appearance | Powder |
| Formula | C20H32O2 | M.Wt | 304.5 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (1S,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-1,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one | ||
| SMILES | CC1CC(=O)CC2C1(C3CCC4(C(C3CC2)CCC4O)C)C | ||
| Standard InChIKey | UXYRZJKIQKRJCF-TZPFWLJSSA-N | ||
| Standard InChI | InChI=1S/C20H32O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h12-13,15-18,22H,4-11H2,1-3H3/t12-,13-,15-,16-,17-,18-,19-,20-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Mesterolone Dilution Calculator
Mesterolone Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.2841 mL | 16.4204 mL | 32.8407 mL | 65.6814 mL | 82.1018 mL |
| 5 mM | 0.6568 mL | 3.2841 mL | 6.5681 mL | 13.1363 mL | 16.4204 mL |
| 10 mM | 0.3284 mL | 1.642 mL | 3.2841 mL | 6.5681 mL | 8.2102 mL |
| 50 mM | 0.0657 mL | 0.3284 mL | 0.6568 mL | 1.3136 mL | 1.642 mL |
| 100 mM | 0.0328 mL | 0.1642 mL | 0.3284 mL | 0.6568 mL | 0.821 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Didemethylpseudoaspidin AA
Catalog No.:BCN3777
CAS No.:142382-28-3
- 7alpha-Hydroxy-4,11-cadinadiene-3,8-dione
Catalog No.:BCN7057
CAS No.:1423809-64-6
- FR 139317
Catalog No.:BCC5733
CAS No.:142375-60-8
- SP2509
Catalog No.:BCC5578
CAS No.:1423715-09-6
- H-D-Phe-pNA
Catalog No.:BCC3015
CAS No.:14235-18-8
- Adefovir Dipivoxil
Catalog No.:BCC5025
CAS No.:142340-99-6
- L-701,324
Catalog No.:BCC6842
CAS No.:142326-59-8
- Teuvincenone H
Catalog No.:BCN6227
CAS No.:142299-73-8
- Shizukaol D
Catalog No.:BCN6226
CAS No.:142279-42-3
- Shizukaol C
Catalog No.:BCN6225
CAS No.:142279-41-2
- Shizukaol B
Catalog No.:BCN6983
CAS No.:142279-40-1
- Kenpaullone
Catalog No.:BCC7047
CAS No.:142273-20-9
- Crovatin
Catalog No.:BCN2517
CAS No.:142409-09-4
- NHS-SS-Biotin
Catalog No.:BCC3581
CAS No.:142439-92-7
- Myricetin 3-O-beta-D-xylopyranosyl(1-2)-beta-D-glucopyranoside
Catalog No.:BCN8140
CAS No.:142449-93-2
- Lobetyolinin
Catalog No.:BCN3322
CAS No.:142451-48-7
- Amthamine dihydrobromide
Catalog No.:BCC6744
CAS No.:142457-00-9
- 3-O-beta-D-apiofuranosyl(1-2)-beta-D-glucopyranosyl rhamnocitrin 4-O-beta-D-glucopyranoside
Catalog No.:BCN8141
CAS No.:142473-99-2
- Glyasperin A
Catalog No.:BCN6228
CAS No.:142474-52-0
- 19-Nortestosterone acetate
Catalog No.:BCC8445
CAS No.:1425-10-1
- MK-5172 sodium salt
Catalog No.:BCC1765
CAS No.:1425038-27-2
- L-690,488
Catalog No.:BCC5667
CAS No.:142523-14-6
- L-690,330
Catalog No.:BCC5666
CAS No.:142523-38-4
- 1,2,3,4,7-Pentamethoxy-9H-xanthen-9-one
Catalog No.:BCN1570
CAS No.:14254-96-7
Chronic Exercise Reduces CETP and Mesterolone Treatment Counteracts Exercise Benefits on Plasma Lipoproteins Profile: Studies in Transgenic Mice.[Pubmed:29058169]
Lipids. 2017 Dec;52(12):981-990.
Regular exercise and anabolic androgenic steroids have opposing effects on the plasma lipoprotein profile and risk of cardio-metabolic diseases in humans. Studies in humans and animal models show conflicting results. Here, we used a mice model genetically modified to mimic human lipoprotein profile and metabolism. They under-express the endogenous LDL receptor gene (R1) and express a human transgene encoding the cholesteryl ester transfer protein (CETP), normally absent in mice. The present study was designed to evaluate the independent and interactive effects of testosterone supplementation, exercise training and CETP expression on the plasma lipoprotein profile and CETP activity. CETP/R1 and R1 mice were submitted to a 6-week swimming training and Mesterolone (MEST) supplementation in the last 3 weeks. MEST treatment increased markedly LDL levels (40%) in sedentary CETP/R1 mice and reduced HDL levels in exercised R1 mice (18%). A multifactorial ANOVA revealed the independent effects of each factor, as follows. CETP expression reduced HDL (21%) and increased non-HDL (15%) fractions. MEST treatment increased the VLDL concentrations (42%) regardless of other interventions. Exercise training reduced triacylglycerol (25%) and free fatty acids (20%), increased both LDL and HDL (25-33%), and reduced CETP (19%) plasma levels. Significant factor interactions showed that the increase in HDL induced by exercise is explained by reducing CETP activity and that MEST blunted the exercise-induced elevation of HDL-cholesterol. These results reinforce the positive metabolic effects of exercise, resolved a controversy about CETP response to exercise and evidenced MEST potency to counteract specific exercise benefits.
A Validated TLC-Densitometric Method for the Determination of Mesterolone in Bulk Material and in Tablets.[Pubmed:26881196]
Biomed Res Int. 2015;2015:230104.
Mesterolone is a synthetic androgenic steroid indicating a weak anabolic activity. A new, simple in use, and economical TLC-densitometric method in normal phase system (NP-TLC) has been developed and validated for the identification and quantitative determination of Mesterolone in bulk drug and in tablet formulation. NP-TLC analysis was performed on aluminium plates precoated with silica gel 60F254 as the stationary phase using chloroform-acetone (40 : 10, v/v) as mobile phase. Densitometric analysis was carried out at lambda = 745 nm after staining with phosphomolybdic acid. These conditions were found to give visible (dark blue) spot and sharp peak, respectively, for Mesterolone at R F 0.75 +/- 0.02 and enabled satisfactory separation of Mesterolone from its related substance (potential impurity). The proposed NP-TLC-densitometric method was validated for specificity, linearity, precision, accuracy, robustness, and sensitivity according to ICH guideline and other validation requirements. The limit of detection (LOD) and limit of quantification (LOQ) were 61.0 ng . spot(-1) and 184.0 ng . spot(-1), respectively. The percent content of Mesterolone in marketed tablet formulation was found to be 99.40% of label claim. The developed TLC-densitometric method can be successfully used in quality control of Mesterolone in bulk material and also tablet formulation.
Mesterolone treatment of aging male syndrome improves lower urinary tract symptoms.[Pubmed:25842579]
J Pak Med Assoc. 2014 Dec;64(12):1366-9.
OBJECTIVE: To investigate the effects of Mesterolone on prostate in patients treated for aging male syndrome. METHODS: The cross-sectional study was conducted from June to September, 2009, at endocrinology and metabolism department of Yuzuncu Yil University, Van, Turkey, andcomprised patients with symptoms of aging male syndrome and/or low testosterone. They were given Mesterolone 50 mg/day per oral for two months. Aging Male Symptoms and International Prostate Symptom Score questionaires and prostate-related quality of life scores were completed and prostate ultrasonography (USG) was performed before and after the treatment. Total testosterone, free testosterone, gonadotropins, estradiol, prolactin, sex-hormone binding globulin, as well as total and free prostate-specific antigen were also studied. RESULTS: Of the 34 patients in the study, 22(64.70%) had their prostate volume increased, while 12(35.29%) had it decreased. The change, however, was not statistically significant (p<0.098). Mesterolone significantly improved Aging Male Symptoms, International Prostate Symptom and prostate-related quality of life scores (p<0.001). These improvements though significant were independent of the changes in prostate volume. Total testosterone, sex-hormone binding globulin andestradiol decreased, while free testosterone showed no change (p<0.002, p<0.001, p<0.024, p<0.337). The fraction of free testosterone increased (p<0.001), while total and free prostate-specific antigen did not change (p<0.368 and p<0.841) CONCLUSION: Mesterolone proved to be a safe alternative in the treatment of Aging Male Syndrome. It also improved lower urinary tract symptoms and prostate-related quality of life.
New potential biomarkers for mesterolone misuse in human urine by liquid chromatography quadrupole time-of-flight mass spectrometry.[Pubmed:25601687]
J Mass Spectrom. 2015 Jan;50(1):153-9.
In this paper, Mesterolone metabolic profiles were investigated carefully. Mesterolone was administered to one healthy male volunteer. Urinary extracts were analyzed by liquid chromatography quadruple time-of-flight mass spectrometry (LC-QTOFMS) for the first time. Liquid-liquid extraction was applied to processing urine samples, and dilute-shoot analyses of intact metabolites were also presented. In LC-QTOFMS analysis, chromatographic peaks for potential metabolites were hunt down by using the theoretical [M-H](-) as target ions in full scan experiment, and their actual deprotonated ions were analyzed in targeted MS/MS mode. Ten metabolites including seven new sulfate and three glucuronide conjugates were found for Mesterolone. Because of no useful fragment ion for structural elucidation, gas chromatography-mass spectrometry instrumentation was employed to obtain structural details of the trimethylsilylated phase I metabolite released after solvolysis. Thus, their potential structures were proposed particularly by a combined MS approach. All the metabolites were also evaluated in terms of how long they could be detected, and S1 (1alpha-methyl-5alpha-androst-3-one-17beta-sulfate) together with S2 (1alpha-methyl-5alpha-androst-17-one-3beta-sulfate) was detected up to 9 days after oral administration, which could be the new potential biomarkers for Mesterolone misuse.
